Nantkwest Inc  

(Public, NASDAQ:NK)   Watch this stock  
Find more results for NK
4.95
-0.01 (-0.20%)
Dec 8 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.90 - 5.10
52 week 2.71 - 8.45
Open 5.04
Vol / Avg. 0.00/217,087.00
Mkt cap 393.30M
P/E     -
Div/yield     -
EPS -1.18
Shares 79.46M
Beta     -
Inst. own 19%
Sep 26, 2017
NantKwest Inc at Cantor Fitzgerald Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -299612.50% -274565.90%
Operating margin -305525.00% -282954.50%
EBITD margin - -274756.80%
Return on average assets -33.19% -35.31%
Return on average equity -39.19% -37.21%
Employees 118 -
CDP Score - -

Address

3530 John Hopkins Ct
SAN DIEGO, CA 92121-1121
United States - Map
+1-858-6330300 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.

Officers and directors

Patrick Soon-Shiong M.D. Chairman of the Board, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Barry J. Simon M.D. President, Chief Operating Officer, Director
Age: 52
Bio & Compensation  - Reuters
Steven Gorlin Vice Chairman of the Board
Age: 79
Bio & Compensation  - Reuters
Richard J. Tajak Interim Chief Financial Officer
Age: 64
Bio & Compensation  - Reuters
Sonja Nelson Chief Accounting Officer
Age: 44
Bio & Compensation  - Reuters
Michael D. Blaszyk Independent Director
Age: 64
Bio & Compensation  - Reuters
Frederick W. Driscoll Independent Director
Age: 66
Bio & Compensation  - Reuters
John T. Potts Jr. M.D. Independent Director
Age: 85
Bio & Compensation  - Reuters
John C. Thomas Jr. Independent Director
Age: 62
Bio & Compensation  - Reuters